NasdaqGS:RAREBiotechs
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After FDA Acceptance Of UX111 Resubmitted BLA
Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted biologics license application for UX111, a gene therapy for Sanfilippo syndrome Type A, with an accelerated approval decision expected later this year.
See our latest analysis for Ultragenyx Pharmaceutical.
The FDA milestones around UX111 and UX016 have arrived against a mixed backdrop, with a sharp 18.5% 7 day share price return contrasting with a 1 year total shareholder return of 28.84% and a 5 year...